Inozyme

OverviewSuggest Edit

Inozyme is a biopharmaceutical company specializing in the developing of novel therapeutics to treat rare metabolic diseases. The Company's area of expertise is disorders of paradoxical mineralization and its lead drug is an enzyme replacement therapy in pre-clinical development.

TypePrivate
Founded2016
HQBoston, MA, US
Websiteinozyme.com

Latest Updates

Employees (est.) (Sept 2021)53
Cybersecurity ratingBMore

Key People/Management at Inozyme

Axel Bolte

Axel Bolte

Co-Founder, Director, President and Chief Executive Officer
Doug Treco

Doug Treco

Chairman
Henric Bjarke

Henric Bjarke

Senior Vice President and Chief Operating Officer
Stephen Dipalma

Stephen Dipalma

Interim Chief Financial Officer
Reinaldo M. Diaz

Reinaldo M. Diaz

Director
Gayle Gironda

Gayle Gironda

Senior Vice President of Human Resources
Show more

Inozyme Office Locations

Inozyme has an office in Boston
Boston, MA, US (HQ)
321 Summer St #400
Boston, MA, US
321 Summer St floor 4
Boston, MA, US
451 D St #911
Show all (3)

Inozyme Financials and Metrics

Summary Metrics

Founding Date

2016

Inozyme total Funding

$116 m

Inozyme latest funding size

$67 m

Time since last funding

2 years ago

Inozyme investors

Inozyme's latest funding round in April 2019 was reported to be $67 m. In total, Inozyme has raised $116 m
Show all financial metrics

Inozyme Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Inozyme Online and Social Media Presence

Embed Graph

Inozyme News and Updates

Inozyme Pharma to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference

BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer…

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency

INZ-701 was previously granted Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for ENPP1 Deficiency INZ-701 was previously granted Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for ENPP1 Deficiency

Inozyme Pharma Announces Appointment of Gayle Gironda as Senior Vice President, Human Resources

BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that Gayle Gironda has been appointed as senior vice president of human resources. Ms.…

Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 Deficiency

- Clinical trial initiation expected in mid-2021 –- Preliminary safety and biomarker data expected by the end of 2021 -

Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business Highlights

– Filed Clinical Trial Application for INZ-701 for ABCC6 Deficiency in Europe; on track to initiate Phase 1/2 clinical trial in mid-2021 –

Inozyme Pharma Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency

Results presented at the European Calcified Tissue Society Congress provide first evidence of increased plasma pyrophosphate (PPi) levels and reduced calcification with an enzyme replacement therapy in an animal model of PXE Results presented at the European Calcified Tissue Society Congress provide…
Show more

Inozyme Blogs

Inozyme Pharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights

The post Inozyme Pharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights appeared first on Inozyme Pharma.

Inozyme Pharma Announces Closing of Initial Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

The post Inozyme Pharma Announces Closing of Initial Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares appeared first on Inozyme Pharma.

Inozyme Pharma Announces Pricing of Initial Public Offering

The post Inozyme Pharma Announces Pricing of Initial Public Offering appeared first on Inozyme Pharma.

Inozyme Pharma Announces Changes to its Board of Directors

The post Inozyme Pharma Announces Changes to its Board of Directors appeared first on Inozyme Pharma.

Inozyme Pharma and GACI Global Initiate Patient Burden of Disease Study to Improve the Understanding of the Severity and Impact of Disease in Patients with ENPP1 Deficiency and ABCC6 Deficiency

The post Inozyme Pharma and GACI Global Initiate Patient Burden of Disease Study to Improve the Understanding of the Severity and Impact of Disease in Patients with ENPP1 Deficiency and ABCC6 Deficiency appeared first on Inozyme Pharma.

Inozyme Pharma Expands Medical Leadership Team

The post Inozyme Pharma Expands Medical Leadership Team appeared first on Inozyme Pharma.

Inozyme Frequently Asked Questions

  • When was Inozyme founded?

    Inozyme was founded in 2016.

  • Who are Inozyme key executives?

    Inozyme's key executives are Axel Bolte, Doug Treco and Henric Bjarke.

  • How many employees does Inozyme have?

    Inozyme has 53 employees.

  • Who are Inozyme competitors?

    Competitors of Inozyme include Integra, Aquinnah Pharmaceuticals and Batavia Biosciences.

  • Where is Inozyme headquarters?

    Inozyme headquarters is located at 321 Summer St #400, Boston.

  • Where are Inozyme offices?

    Inozyme has an office in Boston.

  • How many offices does Inozyme have?

    Inozyme has 3 offices.